Completed PHASE3 INTERVENTIONAL 2-arm NCT01001364

A Comparative Study Between Foraseq and Formoterol/Budesonide Inhalation Capsules in Patients with Asthma (CAINAS)

A Phase III, Randomized, Open-Label, Non-Inferiority Comparative Study Between Foraseq Inhalation Capsules 12/200 Μg and Formoterol/ Budesonide Inhalation Capsules 12/200 Μg Eurofarma in Patients with Asthma

Sponsor: Eurofarma Laboratorios S.A.

Conditions ASTHMA

Interventions Foraseq Formoterol/Budesonide

Updated 6 times since 2017 Last updated: Mar 17, 2025 Started: Feb 28, 2010 Primary completion: Apr 30, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates ASTHMA and is currently completed. Eurofarma Laboratorios S.A. leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Apr 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eurofarma Laboratorios S.A.

Data source: Eurofarma Laboratorios S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil